MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System

/PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VATE), today announced amendments to its...

Related Keywords

China ,United States ,Shenzhen ,Guangdong ,Huadong ,American ,Richardb Dorshow , ,Center Study Establishing Feasibility ,Medibeacon Inc ,Huadong Medicine Co Ltd ,Shenzhen Stock Exchange ,American Society Of Nephrology ,Life Sciences ,Prnewswire Medibeacon Inc ,Beacon Inc ,Shenzhen Stock ,Huadong Medicine ,Glomerular Filtration Rate ,American Society ,Glomerular Filtration Rate Measurement ,Clinical Results ,Pilot Multi Center Study Establishing Feasibility ,Medibeacon Chief Scientific Officer Richard ,Kidney Disease ,Nonclinical Assays ,Device Testing ,Device Manufacturing ,Innovative Medical Device ,Medibeacon Transdermal ,Transdermal Derived Glomerular Filtration Rate ,Investigational Device Exemptions ,